20例NMOSD患者CD4+CD25+FoxP3+调节性T细胞数量和FoxP3 mRNA的表达水平

doi:10.6040/j.issn.1671-7554.0.2021.1525

摘要/Abstract

摘要： 目的评估视神经脊髓炎谱系疾病(NMOSD)患者中CD4⁺CD25⁺FoxP3⁺调节性T细胞(Treg)的百分比,以及叉头蛋白3(FoxP3)mRNA的表达水平。方法采用病例对照研究法以20例NMOSD患者(NMOSD组)和20例健康受试者(正常对照组)为研究对象,收集外周血单个核细胞,使用荧光素记的CD4、CD25和FoxF3单克隆抗体,采用流式细胞术检测CD4⁺CD25⁺FoxP3⁺Treg细胞百分比,采用实时聚合酶链反应法检测FoxP3基因表达。通过酶联免疫吸附试验检测转化生长因子β1(TGF-β1)、干扰素γ(IFN-γ)和白介素10(IL-10)的水平。结果与正常对照组相比,NMOSD组CD4⁺CD25⁺FoxP3⁺Treg细胞百分比和FoxP3 mRNA表达水平显著降低,差异有统计学意义(P<0.05)。NMOSD组IFN-γ水平显著升高(P<0.05),IL-10水平降低(P<0.05),但TGF-β1水平无明显差异(P>0.05)。结论 NMOSD可能与循环CD4⁺CD25⁺FoxP3⁺Treg细胞功能的丧失以及FoxP3基因表达水平降低有关。

关键词: 视神经脊髓炎谱系疾病, CD4⁺CD25⁺FoxP3⁺T调节细胞, 叉头蛋白3, 转化生长因子β1, 干扰素γ, 白介素10

Abstract: Objective To assess the percentage of CD4⁺CD25⁺FoxP3⁺ regulatory T(Treg)cells and the mRNA expression of forkhead box protein 3(FoxP3)in patients with neuromyelitis optica spectrum disorders(NMOSD). Methods The case-control study compared 20 NMOSD patients with 20 healthy controls. The mononuclear cells in peripheral blood were collected. The percentage of CD4⁺CD25⁺FoxP3⁺ Treg cells was measured with flow cytometry using specific monoclonal antibodies recognizing CD4, CD25 and FoxP3 markers. FoxP3 gene expression was determined with real-time polymerase chain reaction. The expressions of transforming growth factor β1(TGF-β1), interferon γ(IFN-γ), and interleukin 10(IL-10)were determined with enzyme-linked immunosorbent assay. Results The percentage of CD4⁺CD25⁺FoxP3⁺ Treg cells and the mRNA expression of FoxP3 were significantly decreased in NMOSD patients compared with those in the controls(P<0.05). NMOSD patients had significantly increased IFN-γ(P<0.05)but decreased IL-10(P<0.05)levels, while there was no significant difference in the level of TGF-β1. Conclusion NMOSD may be associated with an abrogated function of circulating CD4⁺CD25⁺FoxP3⁺ Treg cells and a decreased level of FoxP3 gene expression.

Key words: Neuromyelitis optica spectrum disorders, CD4⁺CD25⁺FoxP3⁺ regulatory T cells, Forkhead box protein 3, Transforming growth factor-β1, Interferon-γ, Interleukin-10

中图分类号:

R744.5

李鸿皓,于晶,陈亚丽,郭守刚. 20例NMOSD患者CD4⁺CD25⁺FoxP3⁺调节性T细胞数量和FoxP3 mRNA的表达水平[J]. 山东大学学报 (医学版), 2022, 60(4): 50-54.

LI Honghao, YU Jing, CHEN Yali, GUO Shougang. Evaluation of CD4⁺CD25⁺FoxP3⁺ regulatory T cells and FoxP3 mRNA expression in 20 NMOSD patients[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 50-54.

参考文献

[1] Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide [J]. Front Neurol, 2020, 11: 501. doi: 10.3389/fneur.2020.00501. eCollection 2020.
[2] Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models [J]. Mult Scler Relat Disord, 2019, 27: 412-418. doi:10.1016/j.msard.2018.12.002.
[3] Glick AB, Wodzinski A, Fu P, et al. Impairment of regulatory T-cell function in autoimmune thyroid disease [J]. Thyroid, 2013, 23(7): 871-878.
[4] Tao JH, Cheng M, Tang JP, et al. Foxp3, Regulatory T cell, and Autoimmune Diseases [J]. Inflammation, 2017, 40(1): 328-339.
[5] Bergot AS, Buckle I, Cikaluru S, et al. Regulatory T cells induced by single-peptide liposome immunotherapy suppress islet-specific t cell responses to multiple antigens and protect from autoimmune diabetes [J]. J Immunol, 2020, 204(7): 1787-1797.
[6] Wang Y, Zhou Y, Sun X, et al. Cytokine and chemokine profiles in patients with neuromyelitis optica spectrum disorder [J]. Neuroimmunomodulation, 2016, 23(5-6): 352-358.
[7] Zhong X, Wang H, Dai Y, et al. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica [J]. J Neuroimmunol, 2011, 240-241: 104-108. doi: 10.1016/j.jneuroim.2011.10.001.
[8] Yang X, Peng J, Huang X, et al. Association of circulating follicular helper t cells and serum cxcl13 with neuromyelitis optica spectrum disorders [J]. Front Immunol, 2021,12: 677190. doi: 10.3389/fimmu.2021.677190.
[9] Tanaka M, Matsushita T, Tateishi T, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis [J]. Neurology, 2008, 71(13): 974-981.
[10] Vaknin-Dembinsky A, Brill L, Kassis I, et al. T-cell reactivity against AQP4 in neuromyelitis optica [J]. Neurology, 2012, 79(9): 945-946.
[11] Attias M, Al-Aubodah T, Piccirillo CA. Mechanisms of human FoxP3(+)Treg cell development and function in health and disease [J]. Clin Exp Immunol, 2019, 197(1): 36-51.
[12] Kato R, Sumitomo S, Tsuchida Y, et al. CD4(+)CD25(+)LAG3(+)T cells with a feature of th17 cells associated with systemic lupus erythematosus disease activity [J]. Front Immunol, 2019, 10: 1619. doi: 10.3389/fimmu.2019.01619.
[13] Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis [J]. J Neuroinflammation, 2017, 14(1): 117.
[14] Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3 [J]. Science, 2003, 299(5609): 1057-1061.
[15] Fathima N, Narne P, Ishaq M. Association and gene-gene interaction analyses for polymorphic variants in CTLA-4 and FOXP3 genes: role in susceptibility to autoimmune thyroid disease [J]. Endocrine, 2019, 64(3): 591-604.
[16] Zhang Y, Zhang J, Liu H, et al. Meta-analysis of FOXP3 gene rs3761548 and rs2232365 polymorphism and multiple sclerosis susceptibility [J]. Medicine(Baltimore), 2019, 98(38): e17224.
[17] Yang C, Huang XR, Fung E, et al. The regulatory T- cell transcription factor Foxp3 protects against crescentic glomerulonephritis [J]. Sci Rep, 2017, 7(1): 1481.
[18] Attias M, Al-Aubodah T, Piccirillo CA. Mechanisms of human FoxP3(+)T(reg)cell development and function in health and disease [J]. Clin Exp Immunol, 2019, 197: 36-51. doi: 10.1111/cei.13290.
[19] Zheng SG, Wang JH, Gray JD, et al. Natural and induced CD4⁺CD25⁺ cells educate CD4⁺CD25^-cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10 [J]. J Immunol, 2004, 172(9): 5213-5221.
[20] Nie J, Li YY, Zheng SG, et al. FOXP3(+)Treg cells and gender bias in autoimmune diseases [J]. Front Immunol, 2015, 6: 493. doi: 10.3389/fimmu.2015.00493.
[21] Kiernan MG, Coffey JC, Sahebally SM, et al. Systemic molecular mediators of inflammation differentiate between crohns disease and ulcerative colitis, implicating threshold levels of IL-10 and relative ratios of pro-inflammatory cytokines in therapy [J]. J Crohns Colitis, 2020, 14(1): 118-129.
[22] Gran F, Kerstan A, Serfling E, et al. Current developments in the immunology of psoriasis [J]. Yale J Biol Med, 2020, 93(1): 97-110.
[23] Kasat K, Patel H, Predtechenska O, et al. Anti-inflammatory actions of endogenous and exogenous interleukin-10 versus glucocorticoids on macrophage functions of the newly born [J]. J Perinatol, 2014, 34(5): 380-385.
[24] Grondal G, Gunnarsson I, Ronnelid J, et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus [J]. Clin Exp Rheumatol, 2000, 18(5): 565-570.
[25] Jacob SE, Nassiri M, Kerdel FA, et al. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity [J]. Mediators Inflamm, 2003, 12(5): 309-313.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed